Pictured: 3D illustration of a human antibody binding to human cell receptors iStock/iLexx

图为人类抗体与人类细胞受体iStock/iLexx结合的3D图

Bay Area–based Attovia Therapeutics announced Thursday it has secured a $105 million Series B as it looks to advance assets in the hot immunology and inflammation space.

位于湾区的Attovia Therapeutics周四宣布，它已获得1.05亿美元的B系列，以期在热门的免疫学和炎症领域推进资产。

According to biotech entrepreneur Andrew Pannu, the immunology and inflammation (I&I) sector saw $12.3 billion in therapeutic M&A activity last year and would continue to be attractive to investors. In addition, I&I biotech Apogee Therapeutics closed an upsized public offering in March, netting around $483 million.

据生物技术企业家安德鲁·潘努（AndrewPannu）称，去年免疫与炎症（I＆I）部门的治疗性并购活动达到123亿美元，并将继续吸引投资者。此外，I＆I biotech Apogee Therapeutics在3月份完成了一次大规模的公开募股，净赚约4.83亿美元。

.

.

According to Attovia, the newly acquired funds will be used to advance its lead programs, ATTO-1310 and ATTO-002, through initial clinical data readouts. The biotech describes these candidates as “Attobodies,” bispecific antibodies that use a proprietary spatial positioning technology that can bind to two different epitopes on a target molecule..

据Attovia称，新获得的资金将用于通过最初的临床数据读数推进其领先项目ATTO-1310和ATTO-002。生物技术将这些候选物描述为“Attobodies”，即双特异性抗体，它使用专有的空间定位技术，可以与靶分子上的两个不同表位结合。。

ATTO-1310 is a potential first-in-class, long half-life anti-IL31 Attobody that aims to treat atopic dermatitis and other pruritic diseases. The asset is currently in the IND-enabling stage and plans to enter clinical trials by the end of 2024. ATTO-002 is an anti-IL31 x IL13 Attobody intended to treat immune-mediated diseases.

ATTO-1310是一种潜在的一流，半衰期长的抗IL31抗体，旨在治疗特应性皮炎和其他瘙痒性疾病。该资产目前处于IND启用阶段，计划在2024年底进入临床试验。ATTO-002是一种抗IL31 x IL13抗体，旨在治疗免疫介导的疾病。

The biotech plans to advance ATTO-002 to an IND, for an as-yet undetermined indication, in 2025. .

该生物技术公司计划在2025年将ATTO-002升级为IND，以获得尚未确定的适应症。

The company also plans to use the Series B funds to build its pipeline further and develop the Attobody platform, which Attovia describes as ideal for going after hard-to-drug targets.

该公司还计划利用B系列基金进一步建设其管道，并开发Attobody平台，Attovia将其描述为追踪难治性目标的理想选择。

“The strong investor interest and timing of this financing underscore the rapid progress we made with Attovia’s differentiated pipeline since the company inception, and the unique potential of our proprietary platform to develop attractive, next-generation immunology product candidates,” Attovia CEO Tao Fu said in a statement..

Attovia首席执行官陶福（Tao Fu）在一份声明中表示：“投资者的强烈兴趣和融资时机突显了自公司成立以来，我们在Attovia差异化渠道方面取得的快速进展，以及我们专有平台在开发有吸引力的下一代免疫学产品候选人方面的独特潜力。”。。

The Series B round was led by Goldman Sachs Alternatives and had participation from new investors such as Cormorant Asset Management and Nextech Venures. Existing investors participating in the round included Illumina Ventures, Frazier Life Sciences and venBio. Attovia was launched by Frazier Life Sciences and Alamar Biosciences in June last year, with Frazier also leading the biotech’s $60 million Series A. .

B轮由高盛另类投资公司（Goldman Sachs Alternatives）牵头，新投资者如鸬鹚资产管理公司（Cormorant Asset Management）和Nextech Venures也参与了。参与这轮投资的现有投资者包括Illumina Ventures、Frazier Life Sciences和venBio。Attovia由Frazier Life Sciences和Alamar Biosciences于去年6月推出，Frazier还领导了生物技术公司6000万美元的A系列。

Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

泰勒·帕肯（Tyler Patchen）是BioSpace的一名全职作家。你可以通过tyler.patchen@biospace.com.在LinkedIn上关注他。